Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

EJNMMI Research

Table 4 Association of significant hematologic toxicity and potential risk factors

	Significant toxicity (grade ≥ 3)
	Any			Anemia			Leukopenia			Thrombocytopenia
	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p
A
Bone metastases
Presence	1.49	0.18–12.32	0.71	1.09	0.13–9.22	0.94	–	–	–	–	–	–
Disseminated/diffuse	5.08	1.08–23.86	0.04	3.54	0.73–17.29	0.12	–	–	–	–	–	–
Baseline hematologic values
Grade ≥ 2 myelosuppression	3.50	1.08–11.32	0.04	4.00	1.08–14.85	0.04	2.44	0.39–15.28	0.34	1.81	0.32–10.38	0.51
Previous mCRPC therapies
Taxane-based chemotherapy	4.62	1.23–17.28	0.02	3.45	0.86–13.93	0.08	10.7	0.93–124.74	0.06	11.37	1.11–116.98	0.04
²²³Ra-dichloride	0.93	0.27–3.20	0.91	1.45	0.39–5.41	0.58	1.43	0.23–8.85	0.70	0.43	0.46–3.61	0.42
EBRT (bone metastasis)	2.36	0.75–7.67	0.14	1.96	0.54–7.11	0.31	2.90	0.47–17.99	0.25	1.91	0.37–9.58	0.44

(A) Univariate logistic regression. OR: odds ratio, 95%CI: 95% confidence interval and (B) non-parametric rank test, r_s = Spearman’s correlation coefficient